5 Best Diabetes Stocks to Buy Now

3. Pfizer Inc. (NYSE:PFE)

Hedge Fund Holdings: 73 

Based in Manhattan, New York City, Pfizer Inc. (NYSE:PFE) is an American multinational pharmaceutical and biotechnology company which focuses on the production and development of medicines and vaccines for immunology, cardiology, endocrinology, and neurology. As of Q3 2023, the company has managed to maintain hedge fund sentiment around its stock, with 73 funds long the stock. Pfizer Inc. (NYSE:PFE) beat EPS estimates of -$0.34 by $0.17, posting earnings of -$0.17 per share in Q3 2023.

Pfizer Inc. (NYSE:PFE) is a great stock pick for investors interested in generating a stable income from the stock as it is a high-quality dividend growth stock and spells an excellent investment opportunity owing to the robust quality of the company’s financial position, favorable future growth projections, and a sustainable dividend yield of 5.38%. Although the stock has underperformed on an year-over-year basis, it is imperative to understand that 2022 was an anomaly as it arrived at the tail-end of the COVID-19 pandemic. When compared to pre-vaccination levels, revenue for the company has actually increased by 8% and profitability metrics remain solid. Hence, the stock is currently undervalued, making for an amazing entry point for the long-term investor.